Suppr超能文献

Polo-like kinase 1 促进了 Pten 肿瘤抑制因子诱导的前列腺癌的形成。

Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.

机构信息

Department of Biochemistry, Purdue University, West Lafayette, Indiana 47907; Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907.

Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907; Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907.

出版信息

J Biol Chem. 2011 Oct 14;286(41):35795-35800. doi: 10.1074/jbc.C111.269050. Epub 2011 Sep 2.

Abstract

Loss of the tumor suppressor Pten (phosphatase and tensin homolog deleted on chromosome 10) is thought to mediate the majority of prostate cancers, but the molecular mechanism remains elusive. In this study, we demonstrate that Pten-depleted cells suffer from mitotic stress and that nuclear function of Pten, but not its phosphatase activity, is required to reverse this stress phenotype. Further, depletion of Pten results in elevated expression of Polo-like kinase 1 (Plk1), a critical regulator of the cell cycle. We show that overexpression of Plk1 correlates with genetic inactivation of Pten during prostate neoplasia formation. Significantly, we find that elevated Plk1 is critical for Pten-depleted cells to adapt to mitotic stress for survival and that reintroduction of wild-type Pten into Pten-null prostate cancer cells reduces the survival dependence on Plk1. We further show that Plk1 confers the tumorigenic competence of Pten-deleted prostate cancer cells in a mouse xenograft model. These findings identify a role of Plk1 in facilitating loss of Pten-induced prostate cancer formation, which suggests that Plk1 might be a promising target for prostate cancer patients with inactivating Pten mutations.

摘要

抑癌基因 Pten(10 号染色体缺失的磷酸酶及张力蛋白同源物)缺失被认为介导了大多数前列腺癌,但其中的分子机制仍难以捉摸。在这项研究中,我们证实了 Pten 缺失的细胞遭受有丝分裂应激,且 Pten 的核功能(而非其磷酸酶活性)对于逆转这种应激表型是必需的。此外,Pten 的缺失导致 Polo 样激酶 1(Plk1)的表达上调,Plk1 是细胞周期的关键调控因子。我们发现,Plk1 的过表达与前列腺肿瘤形成过程中 Pten 的遗传失活相关。重要的是,我们发现升高的 Plk1 对于 Pten 缺失细胞适应有丝分裂应激以存活至关重要,并且将野生型 Pten 重新引入 Pten 缺失的前列腺癌细胞中可降低对 Plk1 的存活依赖性。我们进一步发现 Plk1 赋予了 Pten 缺失的前列腺癌细胞在小鼠异种移植模型中的致瘤能力。这些发现确定了 Plk1 在促进 Pten 缺失诱导的前列腺癌形成中的作用,这表明 Plk1 可能成为具有失活 Pten 突变的前列腺癌患者的一个有希望的治疗靶点。

相似文献

1
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.
J Biol Chem. 2011 Oct 14;286(41):35795-35800. doi: 10.1074/jbc.C111.269050. Epub 2011 Sep 2.
2
Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.
Protein Cell. 2012 Mar;3(3):182-97. doi: 10.1007/s13238-012-2020-y. Epub 2012 Mar 23.
3
Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle.
J Biol Chem. 2014 May 16;289(20):14066-74. doi: 10.1074/jbc.M114.558155. Epub 2014 Apr 4.
6
PTEN regulates PLK1 and controls chromosomal stability during cell division.
Cell Cycle. 2016 Sep 16;15(18):2476-85. doi: 10.1080/15384101.2016.1203493. Epub 2016 Jul 11.
7
Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.
Mol Cell Biol. 2014 Oct 1;34(19):3642-61. doi: 10.1128/MCB.00814-14. Epub 2014 Jul 21.
8
Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
Mol Cell Biol. 2015 Dec;35(24):4185-98. doi: 10.1128/MCB.00825-15. Epub 2015 Oct 5.
9
The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
Genes (Basel). 2019 Mar 11;10(3):208. doi: 10.3390/genes10030208.
10
Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
J Biol Chem. 2015 Jan 23;290(4):2024-33. doi: 10.1074/jbc.M114.596817. Epub 2014 Dec 10.

引用本文的文献

1
2
PLK1 phosphorylates WRN at replication forks.
J Pharmacol Exp Ther. 2025 Feb;392(2):100051. doi: 10.1016/j.jpet.2024.100051. Epub 2024 Nov 30.
4
Synthetic lethal approaches to target cancers with loss of PTEN function.
Genes Dis. 2023 Nov;10(6):2511-2527. doi: 10.1016/j.gendis.2022.12.015.
5
Cyclers' kinases in cell division: from molecules to cancer therapy.
Cell Death Differ. 2023 Sep;30(9):2035-2052. doi: 10.1038/s41418-023-01196-z. Epub 2023 Jul 29.
7
Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinoma.
J Cancer Res Clin Oncol. 2023 Aug;149(10):6883-6899. doi: 10.1007/s00432-023-04624-2. Epub 2023 Feb 22.
9
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
Eur J Med Chem. 2022 Jan 5;227:113926. doi: 10.1016/j.ejmech.2021.113926. Epub 2021 Oct 21.
10
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
J Med Chem. 2021 Jul 22;64(14):9916-9925. doi: 10.1021/acs.jmedchem.1c00133. Epub 2021 Jul 2.

本文引用的文献

2
3
An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
Clin Cancer Res. 2010 Sep 15;16(18):4666-74. doi: 10.1158/1078-0432.CCR-10-0318. Epub 2010 Aug 3.
4
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.
Nat Rev Drug Discov. 2010 Aug;9(8):643-60. doi: 10.1038/nrd3184.
8
Pten in stromal fibroblasts suppresses mammary epithelial tumours.
Nature. 2009 Oct 22;461(7267):1084-91. doi: 10.1038/nature08486.
9
Principles of cancer therapy: oncogene and non-oncogene addiction.
Cell. 2009 Mar 6;136(5):823-37. doi: 10.1016/j.cell.2009.02.024.
10
Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development.
Curr Opin Cell Biol. 2008 Dec;20(6):650-60. doi: 10.1016/j.ceb.2008.10.005. Epub 2008 Nov 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验